RBM10 and neoplasm: To associate a radiographic response with a pathological response, we next followed a patient (case 3) treated with neoadjuvant osimertinib in a clinical trial (NCT03433469), whose tumor harbored the EGFRL858R and RBM10 Q595* co-occurring mutations.